ArticleCureus2025
Primary Focal Segmental Glomerulosclerosis Presenting With Acute Kidney Injury and Nephrotic Syndrome: A Case Report With Sustained Remission.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome in adults, characterized by segmental scarring of the glomeruli. It can present with proteinuria, hypoalbuminemia, edema, and varying degrees of renal dysfunction. Early diagnosis and treatment are critical to prevent progression to end-stage kidney disease. We report the case of a 53-year-old female who presented with worsening generalized edema, abdominal distension, and significant weight gain. Laboratory workup revealed significant proteinuria, hypoalbuminemia, and acute kidney injury, and kidney biopsy confirmed the diagnosis of FSGS. She was treated with high-dose corticosteroids, followed by initiation of losartan, and over a two-year follow-up period, she achieved and maintained complete remission with stable renal function and no recurrence of proteinuria. This case highlights the importance of prompt diagnosis and early intervention in FSGS. High-dose corticosteroids remain the cornerstone of treatment for primary FSGS, with adjunctive renin-angiotensin system blockade playing a key supportive role. Long-term follow-up is essential to monitor treatment response and maintain remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.